The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
13-May-18
$81 million
Target:
GWA Group Limited’s Door and Access Controls Business
Acquiror:
Allegion plc
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
26-May-17
$415 million
Target:
Chromalox
Acquiror:
Spirax Sarco
Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group
11-May-17
$245 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
01-Dec-15
$164 million
Target:
Incotec Group BV
Acquiror:
Croda International Plc
Advised Croda International Plc, a leading UK listed global specialty chemicals producer, on its acquisition of Incotec Group BV, a Netherlands based provider of seed enhancement technologies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
02-Nov-15
$NA
Target:
Reaction Engines Limited
Acquiror:
BAE Systems plc
Advised Reaction Engines Limited, a privately-held company located in the United Kingdom, on a strategic investment by BAE Systems plc, a leading defense, security and aerospace company based in the United Kingdom, to accelerate the company’s development of a new aerospace engine class
28-Oct-15
$NA
Target:
DataLase Ltd
Acquiror:
Sato Holdings Corporation
Advised Sato Holdings Corporation, a leading global provider of Auto-ID solutions, on its acquisition of a significant minority stake in DataLase Ltd, a UK-based provider of materials for laser coding and marking of products and packaging
14-Oct-15
$330 million
Target:
Professional Service Industries, Inc.
Acquiror:
Intertek Group plc
Advised Intertek Group plc, a leading quality solutions provider to industries worldwide, on its $330 million acquisition of Professional Service Industries, Inc. (“PSI”), a leading US based provider of testing and assurance services to commercial and civil construction markets
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
30-Mar-15
$950 million
Target:
Quindell plc’s Professional Services Division
Acquiror:
Slater and Gordon
Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
19-Feb-15
$8.4 billion
Target:
Rexam plc
Acquiror:
Ball Corporation
Advised Ball Corporation, a leading manufacturer of metal packaging products for the global beverage, food, personal care and household products industries as well as a provider of systems and technologies for the aerospace industry, on the acquisition of Rexam plc, a leading beverage can manufacturer
26-Jun-14
$2.9 billion
Target:
Firth Rixson Limited
Acquiror:
Alcoa Inc.
Advised Alcoa Inc. on the acquisition of Firth Rixson Limited, a leading provider of highly engineered rings, industrial forgings and specialized metal products primarily to the aerospace industry
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
01-May-13
$NA
Target:
Jeminex’s Industrial & Safety division
Acquiror:
Bunzl plc
Advised AMP Capital on the sale of Jeminex’s Industrial & Safety division, Australia’s second largest industrial and safety business with branches across Australia, to Bunzl plc
07-Dec-12
$43 million
Target:
Champion Flour Limited
Acquiror:
Nisshin Seifun Group Inc.
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
15-Jan-11
$105 million
Target:
telerob Holding GmbH
Acquiror:
Cobham plc
Advised the shareholders of telerob Holding GmbH, a German-based market leader in the development and manufacture of advanced bomb disposal robots and integrated threat response vehicles, on the sale of the Company to Cobham plc, the UK-based, internationally operating aerospace, defence and security technology group